Paper17519955
Heparanase in glomerular diseases.
van den Hoven MJ and 5 others. Kidney Int, 2007. Cited by 98 papers, by iCite.
Cite this record
ConductScience Library. Heparanase in glomerular diseases. Papers, record 17519955. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17519955
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Glucuronidase | Major topic |
| Proteinuria | Major topic |
| Heparan Sulfate | |
| Humans | |
| Kidney Glomerulus | |
| Heparanase |
Source PubMed
Cited by58
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 98 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41497483 | Identification and Verification of Biomarkers Related to Polyamine Metabolism in Diabetic Nephropathy. | J Diabetes Res | 2025 | https://conductscience.org/library/papers/41497483 | PubMed |
| 41272309 | The glomerular endothelial glycocalyx as a therapeutic target in proteinuric kidney disease. | Nat Rev Nephrol | 2026 | https://conductscience.org/library/papers/41272309 | PubMed |
| 40860946 | Identification of Neutrophil Extracellular Trap-Related Biomarkers in Diabetic Foot Ulcers Based on Bioinformatics. | J Inflamm Res | 2025 | https://conductscience.org/library/papers/40860946 | PubMed |
| 40495439 | Targeting Heparanase Attenuates Podocyte Injury Induced by Puromycin Aminonucleoside. | J Cell Physiol | 2025 | https://conductscience.org/library/papers/40495439 | PubMed |
| 40453077 | Factor H-related 1 and heparan sulfate architecture contribute to complement dysregulation in C3 glomerulopathy. | Front Immunol | 2025 | https://conductscience.org/library/papers/40453077 | PubMed |
| 39474588 | Complement, Coagulation, and Fibrinolysis: The Role of the Endothelium and Its Glycocalyx Layer in Xenotransplantation. | Transpl Int | 2024 | https://conductscience.org/library/papers/39474588 | PubMed |
| 37456170 | Role of heparanase in sepsis‑related acute kidney injury (Review). | Exp Ther Med | 2023 | https://conductscience.org/library/papers/37456170 | PubMed |
| 37273258 | Early diabetic kidney disease: Focus on the glycocalyx. | World J Diabetes | 2023 | https://conductscience.org/library/papers/37273258 | PubMed |
| 37180718 | Heparanase-2 protein and peptides have a protective effect on experimental glomerulonephritis and diabetic nephropathy. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37180718 | PubMed |
| 35336857 | Increased Heparanase Levels in Urine during Acute Puumala Orthohantavirus Infection Are Associated with Disease Severity. | Viruses | 2022 | https://conductscience.org/library/papers/35336857 | PubMed |
| 34857011 | Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma. | J Exp Clin Cancer Res | 2021 | https://conductscience.org/library/papers/34857011 | PubMed |
| 34681753 | The Heparanase Regulatory Network in Health and Disease. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34681753 | PubMed |
| 33794549 | Biology of the Heparanase-Heparan Sulfate Axis and Its Role in Disease Pathogenesis. | Semin Thromb Hemost | 2021 | https://conductscience.org/library/papers/33794549 | PubMed |
| 33539214 | Rationale for the Role of Heparin and Related GAG Antithrombotics in COVID-19 Infection. | Clin Appl Thromb Hemost | 2021 | https://conductscience.org/library/papers/33539214 | PubMed |
| 32274732 | Heparanase in Acute Kidney Injury. | Adv Exp Med Biol | 2020 | https://conductscience.org/library/papers/32274732 | PubMed |
| 32274705 | Forty Years of Basic and Translational Heparanase Research. | Adv Exp Med Biol | 2020 | https://conductscience.org/library/papers/32274705 | PubMed |
| 31103854 | Targeting Heparanase in Cancer: Inhibition by Synthetic, Chemically Modified, and Natural Compounds. | iScience | 2019 | https://conductscience.org/library/papers/31103854 | PubMed |
| 30858582 | Glycosylation in health and disease. | Nat Rev Nephrol | 2019 | https://conductscience.org/library/papers/30858582 | PubMed |
| 30319431 | Xiao-Shen-Formula, a Traditional Chinese Medicine, Improves Glomerular Hyper-Filtration in Diabetic Nephropathy via Inhibiting Arginase Activation and Heparanase Expression. | Front Physiol | 2018 | https://conductscience.org/library/papers/30319431 | PubMed |
| 29988342 | Alternative Pathway Is Essential for Glomerular Complement Activation and Proteinuria in a Mouse Model of Membranous Nephropathy. | Front Immunol | 2018 | https://conductscience.org/library/papers/29988342 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AGT | 183 | PubTator's text mining | https://conductscience.org/library/genes/183 | NCBI Gene |
| HPSE | 10855 | PubTator's text mining | https://conductscience.org/library/genes/10855 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17519955
GET https://conductscience.org/api/papers/v1/17519955/cited_by?page=2